8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 27, 2026·SEC
Material company update
Mar 5, 2026·SEC
Compass Therapeutics, Inc.(CMPX)Earnings, Financials & Key Ratios
CMPX•NASDAQ
Price updated Jun 19, 2026
AboutCompass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$71M-30.1%
- Net Income-$66M-34.7%
- EPS (Diluted)-0.42-16.7%
- ROE-41.29%-14.5%
CMPX Key Insights
Compass Therapeutics, Inc. (CMPX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 17.6% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Shares diluted 15.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CMPX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CMPX Price & Volume
Compass Therapeutics, Inc. (CMPX) stock price & volume — 10-year historical chart
Loading chart...
CMPX Growth Metrics
Compass Therapeutics, Inc. (CMPX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.45%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-5.93%
Return on Capital
10 Years-59.26%
5 Years-45.58%
3 Years-37.95%
Last Year-43.21%
CMPX Recent Earnings
Compass Therapeutics, Inc. (CMPX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.10+0.0%
$0.10
Rev
—
$818,182
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.09+10.0%
$0.10
Rev
—
$900,000
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.08+42.9%
$0.14
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.14-7.7%
$0.13
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.10vs $0.10+0.0% | —vs $818,182 |
| Q2 2026 | Mar 5, 2026 | $0.09vs $0.10+10.0% | —vs $900,000 |
| Q4 2025 | Nov 5, 2025 | $0.08vs $0.14+42.9% | — |
| Q3 2025 | Aug 11, 2025 | $0.14vs $0.13-7.7% | — |
Based on last 12 quarters of dataView full earnings history →
CMPX Peer Comparison
Compass Therapeutics, Inc. (CMPX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 NKTX | 204.62M | 2.86 | -2.03 | -30.9% | 0.24 | |||
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 EXEL | 13.19B | 51.91 | 18.67 | 6.98% | 35.08% | 40.21% | 0.08 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 |
Compare CMPX vs Peers
Compass Therapeutics, Inc. (CMPX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CMPX Income Statement
Compass Therapeutics, Inc. (CMPX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Mar'19 | Mar'20 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 850K | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | -100% | -100% |
Cost of Goods Sold | 1.92M | 0 | 0 | 0 | 0 | 0 | 0 | 1.47M | 738K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | -1.92M▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 850K▲ 0% | -1.47M▼ 273.2% | -738K▲ 0% |
Gross Margin % | - | - | - | - | - | - | 100% | - | - |
Gross Profit Growth % | - | 100% | - | - | - | - | - | -273.18% | - |
Operating Expenses | 38.31M | 34.05M | 27.81M | 81.88M | 41.66M | 50.36M | 57.48M | 71.37M | 74.43M |
OpEx % of Revenue | - | - | - | - | - | - | 6761.76% | - | - |
Selling, General & Admin | 11.22M | 11.6M | 12.91M | 10.93M | 11.66M | 12.24M | 15.13M | 16.87M | 18.51M |
SG&A % of Revenue | - | - | - | - | - | - | 1780.35% | - | - |
Research & Development | 27.09M | 22.45M | 14.9M | 20.34M | 30M | 38.12M | 42.34M | 55.97M | 56.29M |
R&D % of Revenue | - | - | - | - | - | - | 4981.41% | - | - |
Other Operating Expenses | 0 | 0 | 0 | 50.62M | 0 | 0 | 0 | -1.47M | -370K |
Operating Income | -38.31M▲ 0% | -34.05M▲ 11.1% | -27.81M▲ 18.3% | -81.88M▼ 194.4% | -41.66M▲ 49.1% | -50.36M▼ 20.9% | -56.63M▼ 12.4% | -72.84M▼ 28.6% | -75.17M▲ 0% |
Operating Margin % | - | - | - | - | - | - | -6661.76% | - | - |
Operating Income Growth % | - | 11.12% | 18.32% | -194.41% | 49.13% | -20.91% | -12.43% | -28.63% | - |
EBITDA | -36.39M | -31.93M | -25.41M | -80.26M | -39.75M | -48.47M | -54.87M | -71.37M | -74.05M |
EBITDA Margin % | - | - | - | - | - | - | -6455.53% | - | - |
EBITDA Growth % | - | 12.25% | 20.43% | -215.88% | 50.47% | -21.94% | -13.2% | -30.06% | -23.06% |
D&A (Non-Cash Add-back) | 1.92M | 2.12M | 2.4M | 1.62M | 1.9M | 1.89M | 1.75M | 1.47M | 1.12M |
EBIT | 0 | -34.05M | -27.81M | -81.81M | -41.66M | -50.36M | -56.63M | -72.84M | -73.61M |
Net Interest Income | -104K | -485K | -820K | -341K | 0 | 0 | 7.3M | 6.35M | 7M |
Interest Income | 663K | 743K | 88K | 29K | 2.36M | 0 | 7.3M | 6.35M | 7M |
Interest Expense | 767K | 1.23M | 908K | 370K | 2.36M | 0 | 0 | 0 | 0 |
Other Income/Expense | 233K | -601K | -1.66M | -299K | 2.43M | 7.87M | 7.25M | 6.35M | 7M |
Pretax Income | -38.18M▲ 0% | -34.65M▲ 9.2% | -29.47M▲ 15.0% | -82.18M▼ 178.9% | -39.23M▲ 52.3% | -42.49M▼ 8.3% | -49.38M▼ 16.2% | -66.49M▼ 34.7% | -68.17M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | -5808.82% | - | - |
Income Tax | 103K | 91K | 32K | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.27% | -0.26% | -0.11% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -38.29M▲ 0% | -34.74M▲ 9.3% | -29.5M▲ 15.1% | -82.18M▼ 178.6% | -39.23M▲ 52.3% | -42.49M▼ 8.3% | -49.38M▼ 16.2% | -66.49M▼ 34.7% | -68.17M▲ 0% |
Net Margin % | - | - | - | - | - | - | -5808.82% | - | - |
Net Income Growth % | - | 9.25% | 15.09% | -178.58% | 52.27% | -8.33% | -16.19% | -34.66% | -23.45% |
Net Income (Continuing) | -38.29M | -34.74M | -29.5M | -82.18M | -39.23M | -42.49M | -49.38M | -66.49M | -68.17M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -7.66▲ 0% | -0.67▲ 91.3% | -0.52▲ 22.4% | -1.31▼ 151.9% | -0.35▲ 73.3% | -0.33▲ 5.7% | -0.36▼ 9.1% | -0.42▼ 16.7% | -0.37▲ 0% |
EPS Growth % | - | 91.25% | 22.39% | -151.92% | 73.28% | 5.71% | -9.09% | -16.67% | -5.93% |
EPS (Basic) | -7.66 | -0.67 | -0.52 | -1.31 | -0.35 | -0.33 | -0.36 | -0.42 | - |
Diluted Shares Outstanding | 5M | 52.11M | 56.22M | 62.87M | 105.19M | 127.03M | 137.11M | 157.69M | 186.4M |
Basic Shares Outstanding | 5M | 52.11M | 56.22M | 62.87M | 105.19M | 127.03M | 137.11M | 157.69M | 186.4M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CMPX Balance Sheet
Compass Therapeutics, Inc. (CMPX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Mar'19 | Mar'20 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 58.88M | 26.24M | 50.2M | 147.1M | 194.79M | 153.88M | 132.75M | 209.82M | 195.69M |
Cash & Short-Term Investments | 57.51M | 25.3M | 47.08M | 144.51M | 186.61M | 152.46M | 126.72M | 208.91M | 194.69M |
Cash Only | 57.51M | 25.3M | 47.08M | 144.51M | 34.95M | 24.23M | 43.48M | 30.64M | 55.17M |
Short-Term Investments | 0 | 0 | 0 | 0 | 151.66M | 128.23M | 83.24M | 178.26M | 139.52M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 1.37M | 0 | 0 | 0 | 8.18M | 1.42M | 6.03M | 913K | 1M |
Total Non-Current Assets | 5.74M | 4.14M | 1.71M | 6.65M | 4.85M | 2.99M | 7.65M | 9.77M | 9.48M |
Property, Plant & Equipment | 5.37M | 3.75M | 1.13M | 6.33M | 4.53M | 2.67M | 7.08M | 9.2M | 8.91M |
Fixed Asset Turnover | - | - | - | - | - | - | 0.12x | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 262K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 568K |
Other Non-Current Assets | 115K | 392K | 583K | 320K | 320K | 320K | 568K | 568K | 568K |
Total Assets | 64.63M▲ 0% | 30.38M▼ 53.0% | 51.91M▲ 70.9% | 153.76M▲ 196.2% | 199.65M▲ 29.8% | 156.88M▼ 21.4% | 140.4M▼ 10.5% | 219.59M▲ 56.4% | 205.17M▲ 0% |
Asset Turnover | - | - | - | - | - | - | 0.01x | - | 0.00x |
Asset Growth % | - | -52.99% | 70.87% | 196.19% | 29.84% | -21.42% | -10.5% | 56.4% | 142.52% |
Total Current Liabilities | 8.46M | 9.82M | 10.1M | 10.63M | 16.17M | 7.8M | 8.87M | 13.97M | 10.28M |
Accounts Payable | 1.73M | 629K | 1.06M | 867K | 3.38M | 4.09M | 2.25M | 1.58M | 906K |
Days Payables Outstanding | 328.71 | - | - | - | - | - | - | 393.02 | 1.01K |
Short-Term Debt | 3.69M | 5.58M | 7.47M | 0 | 0 | 0 | 0 | 1M | 1.37M |
Deferred Revenue (Current) | 519K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2.53M | 2.25M | 976K | 1.6M | 1.56M | 1.94M | 2.79M | 11.38M | 8M |
Current Ratio | 6.96x | 2.67x | 4.97x | 13.84x | 12.05x | 19.73x | 14.96x | 15.02x | 19.04x |
Quick Ratio | 6.96x | 2.67x | 4.97x | 13.84x | 12.05x | 19.73x | 14.96x | 15.02x | 19.04x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 140.93M | 139.16M | 1.87M | 3.05M | 1.84M | 536K | 6.3M | 8.83M | 8.42M |
Long-Term Debt | 11.06M | 9.29M | 1.87M | 0 | 0 | 0 | 0 | 8.83M | 8.42M |
Capital Lease Obligations | 0 | 0 | 0 | 3.05M | 1.84M | 536K | 6.3M | 0 | 9.23M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 129.87M | 129.87M | 0 | 0 | 0 | 0 | 1K | 0 | 0 |
Total Liabilities | 149.4M | 148.98M | 11.97M | 13.68M | 18.01M | 8.34M | 15.17M | 22.8M | 18.7M |
Total Debt | 14.75M | 14.87M | 9.33M | 4.04M | 2.94M | 1.73M | 6.63M | 9.83M | 9.79M |
Net Debt | -42.76M | -10.43M | -37.74M | -140.48M | -32.01M | -22.5M | -36.85M | -20.81M | -45.38M |
Debt / Equity | - | - | 0.23x | 0.03x | 0.02x | 0.01x | 0.05x | 0.05x | 0.05x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.13x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.61x |
Interest Coverage | -49.95x | -27.73x | -30.63x | -221.11x | -17.65x | - | - | - | - |
Total Equity | -84.77M▲ 0% | -118.6M▼ 39.9% | 39.95M▲ 133.7% | 140.08M▲ 250.7% | 181.64M▲ 29.7% | 148.54M▼ 18.2% | 125.23M▼ 15.7% | 196.79M▲ 57.1% | 186.47M▲ 0% |
Equity Growth % | - | -39.9% | 133.68% | 250.68% | 29.67% | -18.22% | -15.69% | 57.14% | 141.48% |
Book Value per Share | -16.95 | -2.28 | 0.71 | 2.23 | 1.73 | 1.17 | 0.91 | 1.25 | 1.00 |
Total Shareholders' Equity | -84.77M | -118.6M | 39.95M | 140.08M | 181.64M | 148.54M | 125.23M | 196.79M | 186.47M |
Common Stock | 2.39M | 1K | 5K | 10K | 13K | 13K | 13K | 18K | 18K |
Retained Earnings | -87.16M | -121.91M | -151.41M | -233.59M | -272.81M | -315.31M | -364.68M | -431.17M | -449.49M |
Treasury Stock | - | - | - | - | - | - | 0 | 0 | 0 |
Accumulated OCI | -4.1M | 0 | 0 | 0 | -302K | 37K | 210K | 280K | -159K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CMPX Cash Flow Statement
Compass Therapeutics, Inc. (CMPX) cash flow — operating, investing & free cash flow history
| Metric | Mar'19 | Mar'20 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -33.68M | -31.74M | -26.8M | -19.67M | -34.13M | -40.62M | -44.85M | -49.14M | -53.2M |
Operating CF Margin % | - | - | - | - | - | - | -5277.06% | - | - |
Operating CF Growth % | - | 5.75% | 15.56% | 26.63% | -73.52% | -19.03% | -10.43% | -9.56% | -83.61% |
Net Income | -38.29M | -34.74M | -29.5M | -82.18M | -39.23M | -42.49M | -49.38M | -66.49M | -68.17M |
Depreciation & Amortization | 1.92M | 2.12M | 2.4M | 1.62M | 1.9M | 1.89M | 1.75M | -1.4M | -468K |
Stock-Based Compensation | 656K | 915K | 4.02M | 4.03M | 5.33M | 6.12M | 8.56M | 8.37M | 5.85M |
Deferred Taxes | -261K | 109K | 837K | 50.58M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 121K | 116K | -960K | 41K | -871K | 5.97M | -1.65M | 1.2M | 5.11M |
Working Capital Changes | 2.17M | -257K | -3.6M | 6.25M | -1.26M | -2.91M | -4.14M | 9.18M | 4.47M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 992K | -1.1M | 432K | -194K | 2.52M | 708K | -1.84M | -664K | -671K |
Cash from Investing | -2.02M | -466K | 38K | -1.77M | -151.2M | 26.96M | 46.77M | -93.31M | -66.47M |
Capital Expenditures | -2.02M | -466K | -106K | -1.57M | -212K | -30K | -44K | -25K | -89K |
CapEx % of Revenue | - | - | - | - | - | - | 5.18% | - | - |
Acquisitions | 0 | 0 | 144K | 116K | 176K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 144 | -318K | -150.99K | 27K | 0 | 0 | 0 |
Cash from Financing | 64.03M | 37.63K | 48.54M | 118.61M | 75.76M | 2.94M | 17.34M | 129.61M | 133.79M |
Debt Issued (Net) | - | - | - | - | - | - | 0 | 0 | 0 |
Equity Issued (Net) | - | - | - | - | - | - | 18.11M | 130.64M | 143.13M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -159 | 0 | 0 | 0 |
Other Financing | 64.03M | 37.63K | -6.32M | -281K | -480K | -159K | -775K | -1.03M | -9.34M |
Net Change in Cash | 28.33M▲ 0% | -32.21M▼ 213.7% | 21.77M▲ 167.6% | 97.17M▲ 346.3% | -109.57M▼ 212.8% | -10.72M▲ 90.2% | 19.25M▲ 279.7% | -12.84M▼ 166.7% | 14.12M▲ 0% |
Free Cash Flow | -35.7M▲ 0% | -32.21M▲ 9.8% | -26.91M▲ 16.4% | -21.23M▲ 21.1% | -34.34M▼ 61.7% | -40.65M▼ 18.4% | -44.9M▼ 10.5% | -49.17M▼ 9.5% | -53.29M▲ 0% |
FCF Margin % | - | - | - | - | - | - | -5282.24% | - | - |
FCF Growth % | - | 9.78% | 16.45% | 21.09% | -61.71% | -18.38% | -10.46% | -9.51% | -20.47% |
FCF per Share | -7.14 | -0.62 | -0.48 | -0.34 | -0.33 | -0.32 | -0.33 | -0.31 | -0.29 |
FCF Conversion (FCF/Net Income) | 0.88x | 0.91x | 0.91x | 0.24x | 0.87x | 0.96x | 0.91x | 0.74x | 0.78x |
Interest Paid | - | - | - | - | - | - | 0 | 0 | 0 |
Taxes Paid | - | - | - | - | - | - | 0 | 0 | 0 |
CMPX Key Ratios
Compass Therapeutics, Inc. (CMPX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -73.85% | -91.3% | -24.38% | -25.74% | -36.07% | -41.29% | -39.75% |
Return on Invested Capital (ROIC) | - | -946.85% | -6808.37% | -41.87% | -27.4% | -39.61% | -41.33% | -39.52% |
Gross Margin | - | - | - | - | - | 100% | - | - |
Net Margin | - | - | - | - | - | -5808.82% | - | - |
Debt / Equity | - | 0.23x | 0.03x | 0.02x | 0.01x | 0.05x | 0.05x | 0.05x |
Interest Coverage | -27.73x | -30.63x | -221.11x | -17.65x | - | - | - | - |
FCF Conversion | 0.91x | 0.91x | 0.24x | 0.87x | 0.96x | 0.91x | 0.74x | 0.78x |
Revenue Growth | - | - | - | - | - | - | -100% | -100% |
Related:CMPX Dividend History·CMPX Revenue History·CMPX Price History·CMPX P/E History·CMPX Financial Ratios·CMPX Institutional Holders
CMPX SEC Filings & Documents
Compass Therapeutics, Inc. (CMPX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CMPX Frequently Asked Questions
Compass Therapeutics, Inc. (CMPX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Compass Therapeutics, Inc. (CMPX) saw revenue decline by 100.0% over the past year.
Compass Therapeutics, Inc. (CMPX) reported a net loss of $68.2M for fiscal year 2025.
Dividend & Returns
Compass Therapeutics, Inc. (CMPX) has a return on equity (ROE) of -41.3%. Negative ROE indicates the company is unprofitable.
Compass Therapeutics, Inc. (CMPX) had negative free cash flow of $53.3M in fiscal year 2025, likely due to heavy capital investments.